Sørensen Brita Singers, Horsman Michael R
Experimental Clinical Oncology-Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Front Oncol. 2020 Apr 21;10:562. doi: 10.3389/fonc.2020.00562. eCollection 2020.
Tumor hypoxia is a common feature of the microenvironment in solid tumors, primarily due to an inadequate, and heterogeneous vascular network. It is associated with resistance to radiotherapy and results in a poorer clinical outcome. The presence of hypoxia in tumors can be identified by various invasive and non-invasive techniques, and there are a number of approaches by which hypoxia can be modified to improve outcome. However, despite these factors and the ongoing extensive pre-clinical studies, the clinical focus on hypoxia is still to a large extent lacking. Hypoxia is a major cellular stress factor and affects a wide range of molecular pathways, and further understanding of the molecular processes involved may lead to greater clinical applicability of hypoxic modifiers. This review is a discussion of the characteristics of tumor hypoxia, hypoxia-related molecular pathways, and the role of hypoxia in treatment resistance. Understanding the molecular aspects of hypoxia will improve our ability to clinically monitor hypoxia and to predict and modify the therapeutic response.
肿瘤缺氧是实体瘤微环境的一个常见特征，主要是由于血管网络不足且不均一。它与放疗抵抗相关，并导致较差的临床结果。肿瘤中缺氧的存在可通过多种有创和无创技术来识别，并且有多种方法可通过改变缺氧状态来改善预后。然而，尽管存在这些因素以及正在进行的广泛临床前研究，但临床上对缺氧的关注在很大程度上仍然不足。缺氧是一种主要的细胞应激因素，会影响广泛的分子途径，进一步了解所涉及的分子过程可能会使缺氧调节剂在临床上有更大的适用性。本综述讨论了肿瘤缺氧的特征、与缺氧相关的分子途径以及缺氧在治疗抵抗中的作用。了解缺氧的分子层面将提高我们在临床上监测缺氧以及预测和改变治疗反应的能力。
